Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

p53 mediates a default programme of mammary gland involution in the absence of STAT3

Abstract

Previous studies have demonstrated a proapoptotic role for the transcription factor STAT3 in involuting murine mammary epithelium, resulting in delayed involution and lower levels of apoptosis in the STAT3 null gland relative to wild-type controls. As p53 was implicated in the eventual involution of the STAT3 null gland, we examined the effect of STAT3 loss in the mammary gland in a p53 null background. Combined loss of STAT3 and p53 severely perturbed involution, with hyperdelayed loss of epithelium and reappearance of adipocytes. The early apoptotic response was almost completely abrogated, although elevated levels of delayed apoptosis persisted at days 6, 17 and 4 weeks of involution in STAT3-p53 doubly null mammary glands. A 5.7-fold upregulation of the cyclin-dependent kinase inhibitor p21Waf1 at 3 days of involution in STAT3 null glands was abolished in STAT3-p53 doubly null glands – suggesting that the critical factor triggering delayed involution in the STAT3 null gland is a p53-dependent rise in p21Waf1 levels around day 3 of involution. Further, STAT3-p53 doubly null glands showed significantly higher levels of proliferation compared to STAT3 or p53 singly null (or wild-type) glands at days 6, 17 and 4 weeks of involution. Combined loss of STAT3 and p53 therefore results in hyperdelayed involution, demonstrating their synergistic physiological roles in normal involution. This inappropriate retention of p53-deficient cells may represent a novel mechanism of tumour predisposition.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  • Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernandez-Luna JL, Nunez G, Dalton WS and Jove R . (1999). Immunity, 10, 105–115.

  • Chapman RS, Lourenco PC, Tonner E, Flint DJ, Selbert S, Takeda K, Akira S, Clarke AR and Watson CJ . (1999). Genes Dev., 13, 2604–2616.

  • Clarke AR, Purdie, CA, Harrison DJ, Morris RG, Bird CC, Hooper ML and Wyllie AH . (1993). Nature, 362, 849–852.

  • Darnell Jr JE . (2002). Nat. Rev. Cancer, 2, 740–749.

  • Duttaroy A, Qian JF, Smith JS and Wang E . (1997). J. Cell. Biochem., 64, 434–446.

  • Griffiths SD, Clarke AR, Healy LE, Ross G, Ford AM, Hooper ML, Wyllie AH and Greaves M . (1997). Oncogene, 14, 523–531.

  • Jerry DJ, Kuperwasser C, Downing SR, Pinkas J, He C, Dickinson E, Marconi S and Naber SP . (1998). Oncogene, 17, 2305–2312.

  • Li M, Hu J, Heermeier K, Hennighausen L and Furth PA . (1996). Cell Growth Differ., 7, 13–20.

  • Sansom OJ and Clarke AR . (2000). Mutat. Res., 452, 149–162.

  • Selbert S, Bentley, DJ, Melton DW, Rannie D, Lourenco P, Watson CJ and Clarke AR . (1998). Transgenic Res., 7, 387–396.

  • Takeda K, Kaisho T, Yoshida N, Takeda J, Kishimoto T and Akira S . (1998). J. Immunol., 161, 4652–4660.

  • Takeda K, Noguchi K, Shi W, Tanaka T, Matsumoto M, Yoshida N, Kishimoto T and Akira S . (1997). Proc. Natl. Acad. Sci. USA, 94, 3801–3804.

  • Toft NJ, Winton DJ, Kelly J, Howard LA, Dekker M, Riele HT, Arends MJ, Wyllie AH, Margison GP and Clarke AR . (1999). Proc. Natl. Acad. Sci. USA, 96, 3911–3915.

  • Tonner E, Barber MC, Allan GJ, Beattie J, Webster J, Whitelaw CBA and Flint DJ . (2002). Development, 129, 4547–4557.

  • Vousden KH and Lu X . (2002). Nat. Rev. Cancer, 2, 594–604.

  • Yi Y, Shepard A, Kittrell F, Mulac-Jericevic B, Medina D and Said TK . (2004). Mol. Biol. Cell, 15, 2302–2311.

  • Yu H and Jove R . (2004). Nat. Rev. Cancer, 4, 97–105.

  • Zhang Y, Xiong Y and Yarbrough WG . (1998). Cell, 92, 725–734.

Download references

Acknowledgements

This work was supported by the AICR and the Wales Gene Park. We are grateful to Andrea Daniels for technical assistance and to Professor S Akira for providing mice carrying the STAT3 floxed and null alleles.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Alan R Clarke.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Matthews, J., Clarke, A. p53 mediates a default programme of mammary gland involution in the absence of STAT3. Oncogene 24, 3083–3090 (2005). https://doi.org/10.1038/sj.onc.1208512

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/sj.onc.1208512

Keywords

This article is cited by

Search

Quick links